Insider Buying: Profound Medical Corp. (TSE:PRN) Director Buys 14,200 Shares of Stock

Profound Medical Corp. (TSE:PRN - Get Free Report) Director Arun Menawat Dr. purchased 14,200 shares of the firm's stock in a transaction dated Friday, March 14th. The stock was acquired at an average cost of C$10.09 per share, with a total value of C$143,319.75.

Profound Medical Price Performance

PRN stock traded up C$0.33 during trading on Friday, hitting C$10.00. The company had a trading volume of 8,520 shares, compared to its average volume of 6,056. Profound Medical Corp. has a fifty-two week low of C$7.90 and a fifty-two week high of C$15.75. The company has a current ratio of 6.12, a quick ratio of 14.98 and a debt-to-equity ratio of 20.05. The business has a 50 day moving average of C$9.82 and a 200 day moving average of C$10.43. The firm has a market capitalization of C$210.72 million, a price-to-earnings ratio of -5.19 and a beta of 0.81.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.